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Abstract: Aim: To evaluate the effectiveness of the multidisciplinary 
Risk Assessment and Management Program for Patients with Diabetes 
Mellitus (RAMP-DM) in reducing the risks of microvascular complications.  
 
Methods: We conducted a prospective cohort study in 29,670 propensity 
score matched RAMP-DM participants and diabetic subjects under usual 
primary care (14,835 subjects in each group). The study endpoints were 
the first occurrence of any diabetic complications, nonproliferative 
diabetic retinopathy/pre-proliferative diabetic retinopathy (NPDR/pre-
PDR), sight-threatening diabetic retinopathy (STDR) or blindness, 
nephropathy, end-stage renal disease (ESRD), neuropathy, and lower limb 
ulcer or amputation. Log rank-test and multivariable Cox proportional 
hazard regressions were employed to estimate the between-group 
differences in the incidences of study endpoints.  
 
Results: After a median follow-up period of 36 months with >41,000 
person-years, The RAMP-DM had lower incidence in any microvascular 
complications (760 versus 935, adjusted hazard ratio [HR],0.73; 95% 
confidence interval [CI] 0.66 - 0.81; P<0.001). The RAMP-DM group had 
lower incidences in all the specific microvascular complications except 
neuropathy (adjusted HR, 0.94; 95%CI, 0.61 - 1.45; P=0.778). The adjusted 
HR of the RAMP-DM to control group for ESRD, STDR or blindness, and lower 
limb ulcer or amputation were 0.40 (95%CI, 0.24 -0.69 ; P<0.001), 0.55 
(95%CI, 0.39 - 0.78; P=0.001), and 0.49 (95%CI, 0.30 - 0.80; P=0.005), 
respectively.  
 
Conclusion: The RAMP-DM intervention was associated with lower incidences 
of all microvascular complications except neuropathy over a three-year 
follow-up. The encouraging results provided evidence to support that 
structured risk assessment and risk-stratified management provided by a 
multidisciplinary team is effective in reducing microvascular 
complications in diabetic patients. 
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Abstract 
Aim: To evaluate the effectiveness of the multidisciplinary Risk Assessment and Management 
Program for Patients with Diabetes Mellitus (RAMP-DM) in reducing the risks of microvascular 
complications.  
 
Methods: We conducted a prospective cohort study in 29,670 propensity score matched RAMP-
DM participants and diabetic subjects under usual primary care (14,835 subjects in each group). 
The study endpoints were the first occurrence of any diabetic complications, nonproliferative 
diabetic retinopathy/pre-proliferative diabetic retinopathy (NPDR/pre-PDR), sight-
threatening diabetic retinopathy (STDR) or blindness, nephropathy, end-stage renal disease 
(ESRD), neuropathy, and lower limb ulcer or amputation. Log rank-test and multivariable Cox 
proportional hazard regressions were employed to estimate the between-group differences in the 
incidences of study endpoints.  
 
Results: After a median follow-up period of 36 months with >41,000 person-years, The RAMP-
DM had lower incidence in any microvascular complications (760 versus 935, adjusted hazard 
ratio [HR],0.73; 95% confidence interval [CI] 0.66 – 0.81; P<0.001). The RAMP-DM group 
had lower incidences in all the specific microvascular complications except neuropathy (adjusted 
HR, 0.94; 95%CI, 0.61 - 1.45; P=0.778). The adjusted HR of the RAMP-DM to control group 
for ESRD, STDR or blindness, and lower limb ulcer or amputation were 0.40 (95%CI, 0.24 -
0.69 ; P<0.001), 0.55 (95%CI, 0.39 - 0.78; P=0.001), and 0.49 (95%CI, 0.30 - 0.80; P=0.005), 
respectively.  
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Conclusion: The RAMP-DM intervention was associated with lower incidences of all 
microvascular complications except neuropathy over a three-year follow-up. The encouraging 
results provided evidence to support that structured risk assessment and risk-stratified 
management provided by a multidisciplinary team is effective in reducing microvascular 
complications in diabetic patients.  
 
Clinical trial registry: NCT02034695, www.ClinicalTrials.gov 
 
Keywords: diabetes mellitus, risk stratification, multidisciplinary, microvascular complications  
 
List of Abbreviations 
DBP             Diastolic Blood Pressure 
DM          Diabetes Mellitus 
DR Diabetic Retinopathy 
eGFR Estimated Glomerular Filtration Rate 
ESRD End Stage Renal Disease 
HR Hazard Ratio 
ICD-9-CM International Classification of Diseases, Ninth Edition 
ICPC-2   International Classification of Primary Care 
NNT   Number Needed to Treat 
NPDR               Non-Proliferative Diabetic Retinopathy 
RAMP-DM Multidisciplinary Risk Assessment and Management Program for Patients with 
diabetes mellitus 
SBP   Systolic Blood Pressure 
STDR   Sight-threatening Diabetic retinopathy 
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Diabetes mellitus (DM) is one of the most common chronic diseases all over the world. The 
prevalence of DM in the world is estimated to reach 592 million by 2035, with an increase of 
54.2% in total case numbers compared to the year of 2013[1]. China has the largest number of 
diabetic patients. The number of diabetic patients in China is estimated to exceed 129 million in 
2030,  accounting for more than one quarter of the total diabetic cases in the world [2]. In Hong 
Kong, around 1 in 10 people has DM [3], and the prevalence of DM is increasing [4]. Diabetic 
patients have an increased risk of developing microvascular complications, including retinopathy, 
nephropathy and neuropathy. The prevalence of retinopathy and neuropathy is estimated to be 22% 
and 13% respectively in newly diagnosed DM patients [5]. The prevalence of proliferative 
retinopathy is 2% in diabetic patients with less than 5 years of duration of DM, and it increases 
25% in patients with 25 or more years of DM [6]. Diabetic nephropathy develops in 25% Type 2 
DM patients after 10 years after diagnosis [7] and end-stage renal disease (ESRD) develops in 
14% Type 1 DM patients with 10 years duration of DM [8].  
 
However, due to the insidious progress of microvascular complications, patients might be 
undetected or left untreated in early disease stage, which can lead to devastating impact on 
quality of life and life expectancy once the clinical significant complications are developed, such 
as ESRD, sight-threatening diabetic retinopathy (STDR), and amputation. Several modifiable 
risk factors, including HbA1c, blood pressure, eGFR are found to associate with development of 
microvascular complications [9-11].  Early screening and intervention of early stage of 
microvascular complications and modifiable risk factors are critical to prevent or delay the 
progress of disease severity. In recent years, guidelines have recommended risk factor screening 
and risk stratification management [12-14], setting personalized treatment goals based on 
patients’ individual complication risks. Personalized management is advocated as a means of 
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translating the evidence from randomized control trials to real-world settings [15]. However, 
there is a lack of studies on the effectiveness of risk stratification-based personalized 
management [15].  
 
Previous studies on short-term effectiveness of risk-stratification based intervention were 
conducted in the U.S. [16] and U.K. [17] . Both studies reported the increase in the percentages 
of subjects reaching target HbA1c, blood pressure in the intervention group. However, long-term 
effectiveness of the intervention was not reported. In Asia, attempt for the risk stratification 
management was made by the Joint Asia Diabetes Evaluation Program [18]. Clinicians can 
access a web-based comprehensive risk stratification model using an electronic portal. Between 
2007-2009, 3687 people with diabetes across seven Asian countries, including Hong Kong, were 
enrolled [19]. The implementation of the structured care and effectiveness of this care model 
compared to usual care is not clear.  
 
To enhance the management of diabetic subjects in primary care setting in Hong Kong, a 
multidisciplinary risk assessment and management program for patients with diabetes mellitus 
(RAMP-DM) has been operating in public general out-patient clinics since August 2009. The 
details of the intervention have been reported [20]. Compared to diabetic subjects under usual 
care, RAMP-DM group was found to have significant improvement in HbA1c, blood pressure 
control and reduction in cardiovascular events incidences at both 12-month [21] and 36–month 
[22] of follow-up.  
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The RAMP-DM intervention included systematically comprehensive screening of risk factors 
and early stage of diabetic microvascular complications at enrollment, including retinal photo 
examination, foot assessment, renal function test and urine albumin to creatinine ratio 
measurement. It was unclear yet, whether the RAMP-DM intervention was associated with 
reduction in microvascular complications. Therefore, this study aimed at investigating the effects 
of RAMP-DM intervention on the microvascular complications compared to usual primary care 
over 3-year follow-up. It was hypothesized that RAMP-DM participants would have significant 
lower incidences in microvascular complications, especially in the advanced stage diseases.  
 
Methods 
Study design 
A prospective cohort study was conducted to compare the risks of developing different stages of 
three subtypes of diabetic microvascular complications over three years between diabetic 
subjects managed under RAMP-DM and those receiving usual primary care.  
 
RAMP-DM intervention 
The RAMP-DM was a territory-wide primary care service component for patients with DM in 
public primary care clinics in Hong Kong. It was launched since August 2009 by Hong Kong 
Hospital Authority, the sole public healthcare provider in Hong Kong. The details of the RAMP-
DM program have been reported previously [20]. In brief, all the enrolled subjects would 
undergo a comprehensive risk assessment examinations including measurement of basic 
parameters, laboratory test, eye and foot assessment. The case manager, taken by an advanced 
practice nurse would review the examinations results, assessed the cardiovascular risks and 
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stratified patients into ‘very high’, ‘high’, ‘medium’ and ‘low’ risk groups according to the 
modified Joint Asia Diabetes Evaluation cardiovascular risk stratification flow chart [19]. The 
patients were then assigned to receive appropriate interventions and education provided by a 
team of multi-disciplinary healthcare professionals, including Associate Consultants in family 
medicine, Registered Nurses, Advanced Practice Nurses and allied health professionals 
(optometrist, dietitian, podiatrist, physiotherapist, etc) according to their stratified risk level and 
HbA1c level.  According to patients’ risk levels, some RAMP-DM subjects have annual full risk 
factors screening and Nurse Intake Assessment, and others have the full assessment every 2-3 
years with annual blood test and followed-up by their primary care doctors.  
 
Diabetic patients under usual primary care continued to be managed by their primary care 
doctors without risk assessment and stratification. They were also eligible for referral to allied 
health professionals at their doctors’ discretion. 
 
Subjects 
The RAMP-DM aims at covering all diabetic patients in Hong Kong. All patients with DM who 
are followed up regularly at public primary care clinics are eligible to be enrolled in RAMP-DM. 
Patients were invited to join RAMP-DM opportunistically when they saw their primary 
care doctors. The enrollment was on a voluntary basis. Up to 31st December 2013, the end 
date of our study data collection period, there were 147,097 enrolled into RAMP-DM (out of a 
total of 206,238 patients receiving diabetic care under the primary care service of HA from 
August 2008 to July 2013). The remaining people with diabetes were continued to be enrolled 
into RAMP-DM after 31st July 2013, and they served as potential control subjects in this study. 
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We identified study subjects from the Clinical Management System database of the Hospital 
Authority. Inclusion criteria for this study are, 1) Age≥18; 2) Patients with documented 
International Classification of Primary Care (ICPC-2) codes T89/T90 before baseline; 3) Patients 
with at least one public primary clinics attendance before baseline. To evaluate the effectiveness 
of RAMP-DM in reducing primary microvascular complications, subjects with any pre-existing 
microvascular complications were excluded from the analysis. For the control group, patients 
who were enrolled in RAMP-DM on or before 31st July 2013 were also excluded in the analysis. 
 
The baseline for each RAMP-DM participant was the first date of risk assessment of RAMP-DM 
between 1st August 2009 and 31st July 2010. The subjects in control group were DM patients 
continuously managed in usual primary care. We set 31st January 2010, the middle date of 
the baseline among RAMP-DM subjects, as the baseline for the control group. All subjects 
were observed until a study endpoint or three years since their baseline using the date of their last 
follow-up as a censor date.  
 
Ethical approval of this study was granted by the Institutional Review Board of the University of 
Hong Kong/Hospital Authority? Hong Kong West Cluster (UW 10-369), New Territories East 
Cluster (CRE-2010.543), New Territories West Cluster (NTWC/CREC/1091/12), Kowloon East 
and Kowloon Central Cluster (KC/KE-10-0210/ER-3), Kowloon West Cluster (KW/EX/10-317 
(34–04)), and Hong Kong East Cluster (HKEC-2010-093).  
 
Propensity score matching 
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To reduce selection bias, the subjects in the RAMP-DM and control groups were matched using 
propensity score matching. Study subjects were paired based on observable characteristics which 
indicate a similar probability of receiving treatment (similar propensity score), but one of them 
received the intervention and the other did not. The propensity score is the conditional 
probability of receiving the intervention given the observed baseline covariates and it is 
independent of the outcomes. Propensity score matching is appropriate for studies with a large 
sample size and many covariates [23]. A propensity score was generated for each patient, and the 
RAMP-DM intervention was modelled as the dependent variable and the baseline covariates 
were the independent variables. The propensity score matching was conducted using the 
“psmatch2” STATA package by one-to-one matching without replacement and with a caliper of 
0.001, which means the differences of propensity scores for each matched pair was within 0.001. 
The unmatched control subjects were discarded.  
 
The baseline covariates for developing the propensity score were 1) demographic characteristics, 
including age, sex, whether on comprehensive social security assistance; 2) clinical parameters, 
including smoking status, duration of diabetes, HbA1c, low-density lipoprotein cholesterol 
(LDL-C), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglyceride 
systolic blood pressure (SBP), diastolic blood pressure (DBP) and estimated glomerular filtration 
rate (eGFR); 3) treatment modality, including oral glucose-lowering drugs, insulin, anti-
hypertensive drugs and lipid-lowering drugs; and 4) comorbidities, measured by the Charlson 
comorbidity score[24]. 
 
Study endpoints 
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The endpoint for this study was the time to first occurrence of a diabetic microvascular 
complication, which was identified by the International Classification of Diseases, Ninth Edition, 
Clinical Modification (ICD-9-CM) and ICPC-2 codes from the Clinical Management System of 
the Hospital Authority (Supplementary Table).  
 
Data analysis 
The independent t-test or chi-squared test, as appropriate, was employed to compare the 
demographic and clinical parameters between the RAMP-DM and control groups at baseline 
and the end of follow-up. The cumulative incidence rates for each subtype of microvascular 
complications were reported. We constructed the 95% confidence intervals of the incidence 
rates based on the assumption that the observed incident events followed a Poisson 
distribution. We calculated the number needed to treat (NNT) to reduce one diabetes-
related complication by RAMP-DM.  The NNT was calculated as the inverse of the 
absolute risk reduction [25]. The NNT is interpreted as the average number of patients 
needed to treat in order to reduce one unwanted outcomes. The lower the NTT, the more 
effective is the intervention. 
 
For each of the study endpoints, the Kaplan-Meier method was used to estimate the survival 
curves and the log-rank test was used to compare the between group differences. To estimate 
the magnitude of differences in endpoints, multivariable Cox proportional hazards regression 
models were employed to explore the effects of RAMP-DM on the dependent variables of 
each endpoint, adjusting for all the baseline covariates. The hazard ratio (HR) with 95% 
confidence interval of RAMP-DM were reported for each endpoint. The predictive accuracy 
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of each regression model was evaluated using Harrell’s discrimination C-index, ranging from 
0 to 1. A value of 0.5 indicates the model does not have predictive discrimination ability, and 
values of 1 indicate perfect ability to discriminate subjects [26]. Intention to treat analysis was 
adopted.  
 
We performed all the statistical analyses using STATA Version 13.0 (StataCorp LP. College 
Station, Texus, US), and P-value less than 0.05 was considered as statistically significant.  
 
Results 
Baseline characteristics 
From 1st Aug 2009 to 31st July 2010, a total of 18,459 diabetic subjects under primary care were 
enrolled in RAMP-DM. We identified 47,148 potential control subjects who met the inclusion 
criteria for the study. Subjects with any pre-existing microvascular complications were excluded 
in each group, giving 17,804 and 44,809 subjects in RAMP-DM and control groups, respectively. 
Limiting the eligibility to subjects with complete baseline data reduced the sample to 17,528 and 
16,180 in RAMP-DM and control groups, respectively. To reduce selection bias, we further 
refined the study sample using propensity score matching. The final matched sample for this 
study comprised 14,835 RAMP-DM subjects and 14,835 control subjects.  
 
The comparison of baseline characteristics between the two groups is shown in Table 1. At 
baseline, the RAMP-DM and control group had similar values in all the demographic, clinical 
parameters and treatment modality. The average age of the two cohorts was 65, and around 87% 
subjects were on oral glucose-lowering drugs. At the end of follow-up, the RAMP-DM subjects 
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showed significantly lower HbA1c (7.10% vs 7.21%, P<0.001) and SBP (130 mmHg vs 132 
mmHg, P<0.001). The RAMP-DM group showed higher percentages of patients on all the four 
types of drugs (glucose-lowering drugs, anti-hypertensive drugs, lipid-lowering drugs and insulin) 
than the control group at the end of follow-up.  
 
Observed incidence of microvascular complications  
Table 2 shows the observed number of the first diagnoses of each subtype of diabetic 
microvascular complication and the incidence rates over a median follow-up period of 36 months 
among 14,835 subjects in each group. More than 43,000 and 41,000 person-years of observation 
were available for each of the study endpoints in the RAMP-DM and control group, respectively.  
The RAMP-DM group showed lower incidence rates for all the endpoints. NPDR/non-PDR was 
the most prevalent microvascular complication in both groups (535 and 594 retinopathy events in 
RAMP-DM and control group, respectively). Over the observation period, 51 cases of STDR or 
blind occurred in the RAMP-DM group, which was around half that in the control group (90 
cases).  The number needed to treat by RAMP-DM to reduce one microvascular complication 
was 85. 
 
Multivariable Cox Regression Models 
The Kaplan-Meier survival curves for each study end point are shown in Figure 1. For all severer 
microvascular complications, including STDR or blindness (P<0.001), ESRD (P<0.001), ulcer 
or amputation (P=0.009), significant lower incidence rates were observed in RAMP-DM group, 
and the differences became larger over the follow-up period. The incidences of neuropathy were 
almost identical between the two groups (P=0.778).  
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The HR between RAMP-DM and control groups for each study endpoint was estimated by 
multivariable Cox regression models, adjusting for all the baseline covariates. As shown in Table 
3, compared to the control group, the RAMP-DM group significantly reduced the incidence of 
both NPDR/pre-PDR (HR: 0.85, 95% CI: 0.76-0.96, P=0.007) and nephropathy (HR: 0.54, 95% 
CI: 0.45-0.66, P<0.001). The reduction was more evident in severer stages of disease. The HR 
for STDR or blind and ESRD were 0.55 (95%CI: 0.39-0.78, P=0.001) and 0.40(95%CI: 0.24- 
0.69, P<0.001), respectively. The two groups did not show difference in the incidence of 
neuropathy (HR: 0.94, 95% CI: 0.61-1.45, P=0.78), but the RAMP-DM group had substantial 
lower incidence in ulcer or amputation (HR: 0.49, 95% CI: 0.30-0.80, P=0.005). 
 
Discussion 
To the best of our knowledge, this was the first study investigating the long-term effects of a 
multidisciplinary risk-stratification based DM management on microvascular complications in 
Chinese population. With more than 41,000 person-years follow-up, this population-based cohort 
study found that RAMP-DM intervention was associated with reduction in the incidences of all 
the studied diabetic microvascular complications, except neuropathy. The RAMP-DM was more 
effective in reducing the incidences of severe microvascular complications, prompting that 
the HR for developing STDR or blindness, ESRD and ulcer or amputation were 0.55, 0.40 and 
0.49, respectively. These findings provided evidence of the effectiveness of multidisciplinary 
risk-stratification based management in a real world primary setting.  
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Significant lower incidences of retinopathy, nephropathy and amputation were observed in the 
RAMP-DM group, which might be partly attributed to the significant decreases in HbA1c and 
blood pressure observed in the RAMP-DM group. Also, the RAMP-DM group had higher 
percentage of subjects on glucose-lowering drugs, insulin, anti-hypertensive drugs and lipid-
lowering drugs, indicating the RAMP-DM participants were under more intensive treatment. 
HbA1c and blood pressure were found to be associated with the risks of developing diabetic 
retinopathy [9], nephropathy [10] and neuropathy [27] . Previous studies found that intensive 
glucose control were associated with lower incidences of microvascular complications. The 
United Kingdom Prospective Diabetes Study found that, over 10 years follow-up, the intensive 
glucose control reduced the risk of aggregated microvascular complications (RR: 0.75, P=0.0099) 
and retina photocoagulation (RR: 0.71, P=0.0031), but no effects were found in reducing renal 
failure (RR: 0.73, P=0.45) and amputation (RR: 0.61, P=0.099) [28]. The Preterax and 
Diamicron Modified Release Controlled Evaluation trial showed that over 5 years of follow-up, 
the intensive control group showed decrease in the incidence of nephropathy (HR 0.79, P=0.006), 
but not significant effect on retinopathy (HR 0.95, P=0.50) [29]. Compared to interventions that 
only emphasized on medical intervention, multidisciplinary interventions were found to be more 
effective to reduce renal and ophthalmological complications. The Steno-2 study implemented a 
multifactorial intervention including a combination of medications and focused behavior 
modification [30]. It was reported that the intervention group had lower risks for nephropathy 
(relative risk 0.44, P=0.004), retinopathy (relative risk 0.57, P=0.01) and autonomic neuropathy 
(relative risk 0.53, P=0.004) over 13.3 years follow-up compared to the conventional care group . 
A physician-led structured diabetes management program in Germany also showed lower 
incidence of chronic renal insufficiency (relative risk 0.49) and amputation (relative risk 0.63) 
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among the intervention group over 4 years’ follow-up. This program involved education and 
structured evidence-based care by physicians [31].  
 
For each subtype of microvascular complication, we investigated both early stage and advanced 
stage of disease. Interestingly, we found RAMP-DM was more effective in reducing more severe 
stage of disease. RAMP-DM group showed substantial decrease in the incidence of STDR or 
blindness (HR: 0.55, P=0.001), while for the incidence of mild diabetic retinopathy (NPDR/pre-
PDR), the difference between two groups was not evident until 24 months (Figure 1). A possible 
explanation might be that diabetic subjects under RAMP-DM had systematic diabetic 
retinopathy screening, leading to a higher detection rate of diabetic retinopathy. Early detection 
allows more timely management for subjects diagnosed with mild, non-clinical significant 
diabetic retinopathy which might result in a lower incidence of STDR. As diabetic retinopathy 
can be totally asymptomatic until it develops into STDR, early screening for diabetic retinopathy 
is critical in preventing further deterioration by giving timely intensive treatment. A previous 
study showed that a systematic screening program could effectively reduce the prevalence of 
blindness [32]. We should note that even the RAMP-DM group might have higher detect 
rate for NPDR/non-PDR due to the systemic screening, the RAMP-DM management was 
still associated with significant lower incidences of NPDR/non-PDR, which might due to 
better control of blood glucose and blood pressure.  
 
The similar findings were observed for neuropathy. The incidence of mild neuropathy (lower 
limb ulcer or amputation not included) was similar between RAMP-DM and control groups (HR: 
0.940, P=0.778), and the survival curves were almost overlapped (Figure 1). However, RAMP-
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DM group had significantly lower incidence of lower limb ulcer or amputation (HR: 0.493, 
P=0.005), and the difference became more evident after 12 months. Patients enrolled in RAMP-
DM undertook comprehensive foot examination, including physical examination for callosity, 
corn, ulcer, skin infection, deformities, nail pathology, temperature, ischaemic changes and 
peripheral pulses, monofilament test and vibration perception threshold by biothesiometer. Early 
screening was likely to detect more cases asymptomatic neuropathy, leading to relatively “higher” 
incidence of early stage neuropathy in the RAMP-DM group. While the incidence of lower limb 
ulcer or amputation was remarkably lower in the RAMP-DM group. Tight glycemic control [27, 
33], structured education program [34] and multidisciplinary management [30, 31] have been 
found in other studies to decrease the incidence of neuropathy effectively. As a 
multidisciplinary intervention, RAMP-DM included disease education on knowledge, self-care 
and lifestyle during nurse intervention. The risk-stratification management might also raise the 
doctors’ awareness to offer more intensive management of high risk patients. All these efforts 
might contribute to the lower incidences of severer neuropathy in the RAMP-DM group.  
 
We found RAMP-DM was associated with lower incidences of both nephropathy (ESRD not 
included) and ESRD. The presence of asymptomatic nephropathy was mainly through 
albuminuria and eGFR. Diabetic patients under usual primary care also undertook annual blood 
test in Hong Kong. However, patients enrolled in RAMP-DM might receive more intensive 
management in preventing future deterioration of disease, resulting in lower incidences of 
nephropathy and ESRD.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Page 18 of 23 
 
RAMP-DM is the program to stratify diabetic patients with different risk levels so that 
they can receive regular assessment and screening and can be provided early with 
additional interventions or management. RAMP-DM is a way of increasing the focus on 
patients that need a more intensive treatment. The RAMP-DM is organizational investment 
from the Hospital Authority and Food & Health Bureau, that administrative support, central 
information technology system and screening facilities were well provided. In addition, the Food 
& Health Bureau of government commissioned annual audit and evaluation of quality of care 
in three consecutive years, which facilitate quality improvement of diabetes care and adherence 
to the structured risk-stratification based protocol among RAMP-DM patients. Therefore, this 
program could effectively translate the systematic management protocol into the real-world 
setting.  
 
Strength and limitations of this study 
This propensity score matched prospective comparative effectiveness study had several strengths. 
First, the study sample was extracted from the Clinical Management Systemof the Hospital 
Authority, which recorded data on all the people with diabetes managed in the public healthcare 
sector. This population-based sample was highly representative of the Hong Kong population 
with diabetes. Second, large sample size and three-year follow-up presented sufficient subjects to 
examine different stage of diabetic microvascular complications.  Third, comprehensive 
covariates were included to develop propensity score matching for the two groups. The observed 
risk factors that might affect the incidence of diabetic complications were included. We further 
adjusted all the covariates during multivariable Cox regression to minimize any possible bias. 
Fourth, this comparative effectiveness study was based on data obtained from real patients under 
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primary care, and thus applicable to a real-world setting.   Fifth, we used an intention-to-treat 
analysis, giving a more conservative estimate of the effectiveness of RAMP-DM.  
 
Several limitations should be aware when interpreting the results. The important limitation of 
this study was that we could not carry out a randomized study therefore unobserved potential 
confounders might affect the results, although we have minimised this by including as many 
possible covariates as we can in propensity score matching. Second, not all the RAMP-DM 
subjects were included in the analysis due to missing data at baseline and some subjects were 
further excluded due to unavailable matched control pairs. Third, the RAMP-DM patients and 
usual care patients might come from the same or different public primary care clinics. 
Unfortunately, we did not have the clinic information since all the patients were free to 
choose different public primary care clinics for their follow-up. Fourth, three years are not 
long enough to project the long term benefits of RAMP-DM. We need longer follow-up to 
evaluate the longer term effects of RAMP-DM. It would be interesting to see whether the 
effects of RAMP-DM would maintain over a longer term.  
 
Conclusions 
This prospective comparative effectiveness study in a pragmatic primary care setting found that 
RAMP-DM was associated with decreased risks of first occurrence of retinopathy, STDR, 
nephropathy, ESRD, and lower limb ulcer or amputation over a three-year follow-up. These 
findings supplemented the effectiveness of RAMP-DM and provided imperative translational 
evidence of the effectiveness of multidisciplinary risk-stratification based management for 
people with diabetes.  
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Figure legends 
Figure 1.  Kaplan-Meier survival curves 
 
ESRD, End stage renal disease; STDR, Sight-threatening diabetic retinopathy.  
All the P values were from Log-rank test.  
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Table 3. Multivariable Cox proportional hazard regression all endpoints
HR† SE 95%CI P-value
RAMP-DM subjects vs Control subjects (All subjects, N=29,670)
Any microvascular complications 0.73 0.04 (0.66,0.81) <0.001
NPDR/pre-PDR 0.85 0.05 (0.76,0.96) 0.01
STDR or blindness 0.55 0.10 (0.39,0.78) 0.001
Nephropathy 0.54 0.05 (0.45,0.66) <0.001
ESRD 0.40 0.11 (0.24,0.69) <0.001
Neuropathy 0.94 0.21 (0.61,1.45) 0.78
Ulcer or amputation 0.49 0.12 (0.30,0.80) 0.01
† HR>1 indicates greater risk for endpoints
Adjusted for age, sex, whether on CSSA, duration of DM, smoking status, SBP, DBP, HbA1c, TC, H
triglyceride, eGFR, Charlson comorbidity score, glubose-lowering drugs, insulin, anti-hypertensive
drugs and lipid-lowering drugs. 
RAMP-DM vs Control 
ESRD, End stage renal disease;HR=Hazard Ratio;NPDR, non-proliferative diabetic reti
SE=standard error;STDR, Sight-threatening diabetic retinopathy.
Table 3
Supplementary Table. ICD-9CM, ICPC-2 codes for diabetic macrovas
Disease ICPC-2 Codes
Sight threatening diabetic retinopathy (STDR)
or blindness F94
Diabetic nephropathy NA
End-stage renal disease (ESRD) NA
Neuropathy N94
Ulcer of lower limb or amputation L81
Nonproliferative diabetic retinopathy
/pre-proliferative diabetic retinopathy F83
Supplementary Table
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